Francis Collins via Getty Images

NIH cor­rals bio­phar­ma com­pa­nies, reg­u­la­tors and tri­al net­works to co­or­di­nate Covid-19 R&D

Fran­cis Collins’ grand plan to bring or­der to the chaot­ic rush for Covid-19 vac­cines and treat­ments is here.

The pub­lic-pri­vate part­ner­ship that the NIH di­rec­tor teased a few days ago will be known as AC­TIV or Ac­cel­er­at­ing COVID-19 Ther­a­peu­tic In­ter­ven­tions and Vac­cines. By com­pil­ing re­sources, lever­ag­ing ex­ist­ing net­works, lob­by­ing reg­u­la­tors and set­ting up a steer­ing com­mit­tee to pri­or­i­tize promis­ing can­di­dates, the goal is to gen­er­ate more com­pre­hen­sive da­ta quick­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.